Important News
1. Pan Gongsheng: China's current monetary policy stance is supportive, implementing a moderately loose monetary policy.
2. Shanghai Stock Exchange: Greater efforts will be made to encourage the entry of medium- and long-term funds into the market, maintaining a stable and active capital market.
3. China Securities Regulatory Commission: Deepen reforms of the Science and Technology Innovation Board (STAR Market), ChiNext Board (Growth Enterprise Market), and Beijing Stock Exchange, improve the institutional mechanisms for issuance and listing, and cultivate and strengthen patient capital.
4. Zhu Hexin: At the end of July, overseas institutions and individuals held over 10 trillion yuan in domestic stocks, bonds, deposits, and loans.
5. He Lifeng, in meeting with a delegation of U.S. House of Representatives members, emphasized that China and the United States should be guided by the important consensus reached during the call between the two heads of state to promote the stable, healthy, and sustainable development of bilateral economic and trade relations.
Individual Stock News
1. Tianci Materials: A wholly-owned subsidiary signed an 800,000-ton electrolyte supply cooperation agreement with Ruipu Lanjun.
2. Hangzhou Electric Power Co., Ltd.: The company's optical communications business is loss-making, and its copper foil business is still in its infancy.
3. Xiangcai Co., Ltd.: The audit and due diligence related to the acquisition of Great Wisdom has been largely completed. 4. Changchuan Technology: Net profit for the first three quarters is expected to be 827 million to 877 million yuan, a year-on-year increase of 131% to 145%.
5. Guangli Micro: The inquiry transfer price is 65 yuan per share, a 28% discount to the closing price.
6. Yabao Pharmaceutical: The company terminated the clinical trial of its innovative drug SY-009 and set aside 55.7933 million yuan for asset impairment.
7. Oriental Pearl: Plans to invest 244 million yuan to participate in the establishment of the Advanced Computing Phase II Fund and acquire equity in Super Fusion Digital Technology Co., Ltd.
8. Tasly: Its wholly-owned subsidiary, Puyouke, has received approval for a new indication, making it the only recombinant human urokinase product currently approved for marketing in China.
9. Zhongjing Electronics: Plans to raise up to 700 million yuan through a private placement to fund projects such as the intelligent PCB production base project in Thailand.
10. Jinzi Ham: A wholly-owned subsidiary plans to acquire up to a 20% stake in Zhongsheng Microelectronics for up to 300 million yuan. Zhongsheng Microelectronics specializes in the research and development of core electronic chips for high-speed optical modules. 11. Dingxin Communications: The technology licensed from Pingtou Ge is used solely for its independently developed MCU chips and has no connection to AI intelligent reasoning chips.
12. Zhixiang Jintai: Signed a commercialization collaboration agreement with Kangzhe Pharmaceuticals for Viconduta and Selevimab injections, and will receive upfront payments and milestone payments totaling approximately RMB 510 million.
